Qiagen (NYSE:QGEN) Shares Bought by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. raised its stake in Qiagen (NYSE:QGEN) by 3.3% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 57,513 shares of the company’s stock after purchasing an additional 1,844 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Qiagen were worth $2,621,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of the stock. GAMMA Investing LLC boosted its stake in shares of Qiagen by 806.5% during the third quarter. GAMMA Investing LLC now owns 562 shares of the company’s stock worth $26,000 after buying an additional 500 shares during the period. Toronto Dominion Bank purchased a new position in Qiagen during the second quarter worth about $27,000. Massmutual Trust Co. FSB ADV raised its holdings in Qiagen by 39.8% during the third quarter. Massmutual Trust Co. FSB ADV now owns 853 shares of the company’s stock worth $39,000 after purchasing an additional 243 shares in the last quarter. CWM LLC increased its holdings in Qiagen by 12.0% in the second quarter. CWM LLC now owns 2,505 shares of the company’s stock valued at $103,000 after buying an additional 269 shares in the last quarter. Finally, Headlands Technologies LLC increased its holdings in Qiagen by 396.6% in the second quarter. Headlands Technologies LLC now owns 2,741 shares of the company’s stock valued at $113,000 after buying an additional 2,189 shares in the last quarter. Institutional investors and hedge funds own 70.00% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the stock. Jefferies Financial Group reissued a “buy” rating and set a $54.00 price objective (up from $42.00) on shares of Qiagen in a research note on Tuesday, December 10th. HSBC lowered shares of Qiagen from a “buy” rating to a “hold” rating and set a $49.00 price target on the stock. in a report on Thursday, October 17th. Finally, Hsbc Global Res upgraded shares of Qiagen to a “hold” rating in a report on Thursday, October 17th. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, Qiagen presently has an average rating of “Moderate Buy” and a consensus target price of $51.15.

Qiagen Stock Down 1.2 %

Qiagen stock opened at $45.40 on Monday. The company’s 50-day moving average price is $43.21 and its two-hundred day moving average price is $43.72. The stock has a market cap of $10.36 billion, a price-to-earnings ratio of 116.41, a PEG ratio of 3.52 and a beta of 0.35. The company has a current ratio of 2.17, a quick ratio of 1.89 and a debt-to-equity ratio of 0.39. Qiagen has a 52 week low of $39.03 and a 52 week high of $47.44.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.